Mergers and acquisitions – Page 15
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
BusinessPfizer presses hard for AstraZeneca deal
Executives face down international controversy over tax schemes and previous post-merger record
-
Business
Solvay-Ineos PVC deal passes European approval
Firms required to divest plants to maintain competition
-
BusinessBayer wins race to buy Merck & Co consumer care
$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company
-
Business
Insider trading allegations stall Sun–Ranbaxy deal
Companies deny wrongdoing in lead-up to merger announcement
-
Business
Forest Labs buys Furiex for bowel drug
Firm will immediately sell on other assets to Royalty Pharma
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
BusinessSun set on Ranbaxy rescue
Acquiring beleaguered firm will create India’s biggest pharmaceutical company
-
Business
Pharma giants plan new public–private collaborations
AstraZeneca and GSK will partner with UK academics to work on early drug discovery
-
Business
Baxter aims to divide and conquer
Firm will split off its biopharmaceuticals business from medical products
-
Business
Minerals Technologies wins tussle over Amcol
US firm outbids European rival Imerys for polymer and speciality minerals supplier
-
Business
Bayer agrees seed firm takeover in Argentina
Bayer CropScience seeks to grow South American seed business
-
Business
Evonik acquires US silicic acid ester supplier
German chemicals giant expand functional silane production in the US with Silbond purchase
-
BusinessMegamerger brings Actavis into R&D race
$25bn Forest Labs takeover will see generics giant take on patented products
-
BusinessGenerics give injectables a shot
A rash of recent acquisitions sees generics companies eager to enter speciality manufacturing market
-
Business
Merck & Co doubles up on Ablynx research deal
Cancer nanobody R&D partnership could be worth €1.7 billion